Tilray logo
Tilray TLRY
$ 4.83 8.05%
report update icon

Quarterly report 2026-Q3
added 07-28-2026

Tilray Balance Sheet 2025-2011 | TLRY

Brief balance sheet overview of Tilray

The balance sheet is assessed across five available annual reports spanning 2019 to 2023.

The asset base grew from $2.4 billion to $4.3 billion, or +76.4%. Average annual growth of roughly 15.2% was strong.

Liabilities grew more slowly than assets: +38% versus +76.4%. Expansion relied more on equity, improving funding quality.

The equity ratio reached 77% from 11.7%. A high capital share reduces dependence on liabilities.

Net debt to equity stands at 0x; the current burden does not look excessive.

Cash represents 4.8% of assets versus 4% initially, showing how the immediate liquidity reserve changed.

Retained earnings are negative at -$2.4 billion. This reduces the formal capital cushion, although large shareholder returns may have contributed.

What the balance sheet shows

Tilray has a solid balance sheet cushion. Capital and liquidity support development without excessive reliance on debt.

Annual Balance Sheet Tilray

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-172 M -180 M 16.8 M -291 M -321 M 211 M -62.2 M -28.6 M -46.5 M -16.5 M -7.05 M -12.9 K -10.3 K -23.7 K -

Long Term Debt

44.3 M 43.9 M 221 M 118 M 167 M 400 M 482 M 28.3 M 31.8 M - - - - - -

Long Term Debt Current

5.38 M 4 M 2.42 M 6.7 M - - 2.47 M - - - - - - - -

Total Non Current Liabilities

- - - - - - 570 M 96.6 M 31.8 M - - - - - -

Total Current Liabilities

280 M 299 M 433 M 280 M 401 M 181 M 92.4 M 25.9 M - - - - - - -

Total Liabilities

585 M 778 M 977 M 1.01 B 1.56 B 660 M 708 M 140 M 42.1 M 1.27 M 947 K 30 K 11 K 11 K -

Deferred Revenue

- - - - - - 23.7 M 2.61 M 2.8 M - - - - - -

Retained Earnings

-4.85 B -2.66 B -2.42 B -963 M -486 M -61.2 M 12.1 M 27.5 M -4.12 M -8.32 M -8.72 M -272 K -140 K -95.8 K -

Total Assets

2.07 B 4.22 B 4.31 B 5.45 B 6.03 B 2.5 B 2.44 B 1.31 B 316 M 36.3 M 14.3 M 184 K 298 K 342 K -

Cash and Cash Equivalents

222 M 228 M 207 M 416 M 488 M 190 M 96.8 M 487 M - - - - - - -

Book Value

1.49 B 3.44 B 3.33 B 4.44 B 4.47 B 1.84 B 1.73 B 1.17 B 274 M 35 M 13.3 M 154 K 287 K 331 K -

Total Shareholders Equity

1.51 B 3.44 B 3.32 B 4.4 B 4.47 B 1.27 B 285 M 198 M -4.85 M 2.53 M - - - - -

All numbers in USD currency

Quarterly Balance Sheet Tilray

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

43.2 M 43.6 M 43.2 M 43.6 M 44 M 44.3 M 44.6 M 104 M 43.7 M 43.9 M 127 M 130 M 121 M 221 M 223 M 223 M - 402 M 402 M 152 M 165 M 167 M 167 M 15.3 M - 94 M - 14.2 M - - - 8.29 M 9.35 M 9.13 M - 9.43 M 9.43 M 9.43 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

549 M 552 M 549 M 552 M 562 M 585 M - 701 M 778 M 778 M 870 M 778 M 1 B 977 M 969 M 991 M 1.03 B 1.01 B 1.01 B 1.29 B 1.6 B 1.56 B 1.56 B 572 M 701 M 724 M 725 M 611 M 611 M 611 M 611 M 459 M 459 M 459 M 459 M 58.8 M 58.8 M 58.8 M - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-4.92 B -4.89 B -4.92 B -4.89 B -4.85 B -4.85 B - -3.57 B -2.7 B -2.66 B -2.63 B -2.66 B -2.49 B -2.42 B -2.28 B -1.11 B -1.04 B -963 M -963 M -528 M -528 M -486 M -486 M -730 M -727 M -725 M -643 M -430 M -430 M -430 M -430 M -108 M -108 M -108 M -108 M -40.5 M -40.5 M -40.5 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

2.07 B 2.1 B 2.07 B 2.1 B 2.08 B 2.07 B - 3.4 B 4.26 B 4.22 B 4.21 B 4.22 B 4.4 B 4.31 B 4.38 B 5.47 B 5.59 B 5.45 B 5.45 B 5.76 B 5.99 B 6.03 B 6.03 B 946 M 887 M 856 M 916 M 896 M 896 M 896 M 896 M 657 M 657 M 657 M 657 M 53.9 M 53.9 M 53.9 M - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

205 M 247 M 205 M 247 M 265 M 222 M - 200 M 205 M 228 M 146 M 228 M 178 M 207 M 165 M 190 M 491 M 416 M 416 M 332 M 376 M 488 M 488 M 190 M 155 M 137 M 174 M 96.8 M 96.8 M 96.8 M 96.8 M 487 M 487 M 487 M 487 M 2.32 M 2.32 M 2.32 M - 7.53 M - - - - - - - - - - - - - - - - - - - - - - -

Book Value

1.53 B 1.55 B 1.53 B 1.55 B 1.52 B 1.49 B - 2.7 B 3.48 B 3.44 B 3.34 B 3.44 B 3.4 B 3.33 B 3.41 B 4.48 B 4.56 B 4.44 B 4.44 B 4.47 B 4.39 B 4.47 B 4.47 B 374 M 187 M 131 M 190 M 285 M 285 M 285 M 285 M 198 M 198 M 198 M 198 M -4.85 M -4.85 M -4.85 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

1.56 B 1.58 B 1.56 B 1.58 B 1.54 B 1.51 B 2.7 B 2.73 B 3.48 B 3.44 B 3.34 B 3.44 B 3.38 B 3.32 B 3.41 B 4.48 B 4.56 B 4.4 B 4.4 B 4.47 B 4.39 B 4.47 B 4.46 B 374 M 187 M 131 M 190 M 285 M 285 M 285 M 285 M 198 M 198 M 198 M 198 M -4.85 M -4.85 M -4.85 M - 2.53 M - - - 9.9 M - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Tilray, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Drug manufacturers

Issuer Price % 24h Market Cap Country
ProPhase Labs ProPhase Labs
PRPH
- - $ 5.07 M usaUSA
Evoke Pharma Evoke Pharma
EVOK
- - $ 36.6 M usaUSA
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 7.65 0.26 % $ 114 M usaUSA
Cronos Group Cronos Group
CRON
$ 3.29 2.49 % $ 1.26 B canadaCanada
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
- - $ 2.06 B franceFrance
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
Evolus Evolus
EOLS
$ 8.6 5.13 % $ 554 M usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
Harrow Health Harrow Health
HROW
$ 41.64 5.36 % $ 1.53 B usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
Assertio Holdings Assertio Holdings
ASRT
- - $ 150 M usaUSA
Zynerba Pharmaceuticals Zynerba Pharmaceuticals
ZYNE
- - $ 55.5 M usaUSA
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
Zomedica Corp. Zomedica Corp.
ZOM
- -0.21 % $ 98 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
Bausch Health Companies Bausch Health Companies
BHC
$ 6.89 0.14 % $ 2.56 B canadaCanada
Emergent BioSolutions Emergent BioSolutions
EBS
$ 4.89 4.82 % $ 262 M usaUSA
China Pharma Holdings China Pharma Holdings
CPHI
$ 1.08 0.93 % $ 4.63 M chinaChina
OrganiGram Holdings OrganiGram Holdings
OGI
$ 1.24 2.48 % $ 118 M canadaCanada
Rockwell Medical Rockwell Medical
RMTI
$ 7.5 0.13 % $ 270 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 5.15 0.19 % $ 257 M usaUSA
Perrigo Company plc Perrigo Company plc
PRGO
$ 13.96 7.59 % $ 1.93 B usaUSA
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 1.36 4.62 % $ 2.29 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
$ 9.74 7.27 % $ 852 M usaUSA
TherapeuticsMD TherapeuticsMD
TXMD
$ 2.03 1.0 % $ 23.5 M usaUSA
Veru Veru
VERU
$ 2.64 1.93 % $ 38.7 M usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 1.04 5.08 % $ 310 M canadaCanada
cbdMD cbdMD
YCBD
$ 0.49 4.26 % $ 1.97 M usaUSA
Aurora Cannabis Aurora Cannabis
ACB
$ 3.91 6.54 % $ 214 M canadaCanada
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 4.83 0.31 % $ 191 M usaUSA
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 1.91 6.7 % $ 242 M usaUSA
Pacira BioSciences Pacira BioSciences
PCRX
$ 24.36 1.5 % $ 1.09 B usaUSA
Sundial Growers Sundial Growers
SNDL
$ 1.31 6.5 % $ 338 M canadaCanada